IART:NGS-Integra LifeSciences Holdings Corporation

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 53.8

Change

-0.43 (-0.79)%

Market Cap

USD 3.08B

Volume

0.33M

Analyst Target

USD 60.46
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Integra Lifesciences Holdings Corp is engaged in development, manufacturing, and marketing of product lines from its technology for applications ranging from burn and deep tissue wounds to repair of dura mater in the brain to repair of nerve and tendon.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.78 (-0.56%)

USD 51.34B
ALGN Align Technology Inc

+0.02 (+0.01%)

USD 24.63B
BRKR Bruker Corporation

+0.08 (+0.09%)

USD 12.93B
PODD Insulet Corporation

+2.22 (+1.31%)

USD 11.49B
SWAV Shockwave Medical Inc

+3.02 (+0.94%)

USD 10.25B
MASI Masimo Corporation

+2.37 (+1.64%)

USD 7.14B
AXNX Axonics Modulation Technologie..

+0.07 (+0.10%)

USD 3.51B
IRTC iRhythm Technologies Inc

+0.24 (+0.21%)

USD 3.36B
QDEL Quidel Corporation

-0.32 (-0.66%)

USD 3.14B
LIVN LivaNova PLC

+0.07 (+0.13%)

USD 3.02B

ETFs Containing IART

DWSH AdvisorShares Dorsey Wrig.. -0.80 % 0.00 %

-0.07 (-0.99%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.29% 68% D+ 66% D+
Dividend Return N/A N/A N/A N/A F
Total Return 19.29% 68% D+ 65% D
Trailing 12 Months  
Capital Gain -14.60% 64% D 44% F
Dividend Return N/A N/A N/A N/A F
Total Return -14.60% 64% D 43% F
Trailing 5 Years  
Capital Gain 357.68% 89% A- 96% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 357.68% 89% A- 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 51.97% 85% B 88% B+
Dividend Return 51.97% 85% B 88% B+
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 61.41% 26% F 24% F
Risk Adjusted Return 84.63% 91% A- 89% A-
Market Capitalization 3.08B 96% N/A 89% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 52.10 50% 18%
Price/Book Ratio 3.32 54% 35%
Price / Cash Flow Ratio 0.00 76% 84%
Price/Free Cash Flow Ratio 0.00 76% 83%
Management Effectiveness  
Return on Equity 6.89% 84% 60%
Return on Invested Capital N/A N/A N/A
Return on Assets 4.62% 89% 78%
Debt to Equity Ratio 97.48% 19% 23%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector